CIK 0001674632
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Beta Bionics, Inc.
Sign in to watch- Ticker
- BBNX
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 475386878
- Phone
- +1 949-427-7785
- Business address
- 11 HUGHES, IRVINE, CA, 92618
- Former names
- Beta Bionics, Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,298,305
- in 21 filings, $2.6M under 10b5-1 plans
Net −$3,298,305. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-16 | Hopman Mark Chief Commercial Officer | Exercise or conversion 10b5-1 | +775 | $5.10 | $4K | 54,918 |
| 2026-11-16 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −775 | $16.22 | $13K | 54,143 |
| 2026-11-16 | Hopman Mark Chief Commercial Officer | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −775 | 20,950 | ||
| 2026-11-02 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −370 | $16.90 | $6K | 54,143 |
| 2026-10-26 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −821 | $20.00 | $16K | 54,513 |
| 2026-10-14 | Hopman Mark Chief Commercial Officer | Sale | −775 | $17.35 | $13K | 55,334 |
| 2026-10-01 | Hopman Mark Chief Commercial Officer | Sale | −370 | $18.96 | $7K | 56,109 |
| 2026-09-16 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −30,779 | $20.13 | $620K | 56,479 |
| 2026-09-14 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −775 | $15.52 | $12K | 86,382 |
| 2026-09-09 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −35,994 | $18.46 | $665K | 88,033 |
| 2026-09-09 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −36,870 | $18.46 | $681K | 87,157 |
| 2026-09-02 | Hopman Mark Chief Commercial Officer | Sale | −5,327 | $19.11 | $102K | 124,027 |
| 2026-06-24 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −1,258 | $15.01 | $19K | 129,354 |
| 2026-06-04 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −275 | $12.31 | $3K | 130,612 |
| 2026-06-02 | Hopman Mark Chief Commercial Officer | Sale | −5,329 | $12.61 | $67K | 130,887 |
| 2026-03-04 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −353 | $11.57 | $4K | 139,133 |
| 2026-03-02 | Hopman Mark Chief Commercial Officer | Sale | −834 | $12.36 | $10K | 139,486 |
| 2026-02-27 | Hopman Mark Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +91,520 | 91,520 | ||
| 2026-02-27 | Hopman Mark Chief Commercial Officer | Grant or award | +109,105 | 140,320 | ||
| 2026-02-27 | Hopman Mark Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +58,749 | 58,749 |
Page 1 of 3 · 45 trades